BioMarin Pharmaceutical Inc. vs Evotec SE: A Gross Profit Performance Breakdown

Biotech Giants: A Decade of Profit Growth

__timestampBioMarin Pharmaceutical Inc.Evotec SE
Wednesday, January 1, 201462127600029378000
Thursday, January 1, 201573788700037987000
Friday, January 1, 201690723400058554000
Sunday, January 1, 2017107186000082568000
Monday, January 1, 20181175948000112016000
Tuesday, January 1, 20191344582000132891000
Wednesday, January 1, 20201336183000125743000
Friday, January 1, 20211375760000151543000
Saturday, January 1, 20221612370000174065000
Sunday, January 1, 20231842161000175051000
Loading chart...

In pursuit of knowledge

BioMarin Pharmaceutical Inc. vs Evotec SE: A Decade of Gross Profit Growth

In the competitive landscape of biotechnology, BioMarin Pharmaceutical Inc. and Evotec SE have showcased remarkable growth trajectories over the past decade. From 2014 to 2023, BioMarin's gross profit surged by nearly 200%, reflecting its robust market strategies and innovative product pipeline. In contrast, Evotec SE, while smaller in scale, demonstrated a commendable growth of approximately 500%, highlighting its agility and strategic partnerships.

Key Insights

  • BioMarin's Dominance: By 2023, BioMarin's gross profit reached nearly $1.84 billion, a testament to its sustained market leadership.
  • Evotec's Rapid Growth: Despite starting with a modest $29 million in 2014, Evotec's gross profit climbed to $175 million by 2023, underscoring its rapid expansion.

This analysis provides a compelling narrative of how strategic focus and market dynamics can drive financial success in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025